Clovis shares slide on Rubraca trial discontinuation

08:00 EDT 16 Apr 2019 | BioPharmaDive

An independent review concluded the biotech's PARP inhibitor was unlikely to provide a meaningful clinical benefit to metastatic bladder cancer patients.

Original Article: Clovis shares slide on Rubraca trial discontinuation


More From BioPortfolio on "Clovis shares slide on Rubraca trial discontinuation"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...